Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Computerized Thermal Imaging CIO (formerly COII) -- Ignore unavailable to you. Want to Upgrade?

To: Prospector who wrote (535)	6/4/1998 10:46:00 PM
From: chirodoc	Respond to of 6039

THERMAL IMAGING CAN MEASURE DECREASED BLOOD FLOW AGAIN PARTNER, I DUG AROUND AND FOUND ANOTHER NUGGET....LOOKS LIKE COULD BE A COMPUTERIZED CLINICAL JOURNAL CURTIS Int J Clin Monit Comput 1994 Feb;11(1):31-34 Assessment of chemical lumbar sympathectomy in critical limb ischaemia using thermal imaging. Greenstein D, Brown TF, Kester RC Department of Vascular Surgery, Seacroft Hospital, Leeds, England. Objective assessment of chemical lumbar sympathectomy (CLS) is lacking. Its success is usually judged in terms of the patient's clinical improvement. We have thermographically measured the immediate temperature changes of the lower limb following CLS using a thermal imager (SAN-EI Thermotracer 6T61). Seven patients with critical limb ischaemia and one patient with Raynaud's phenomenon underwent unilateral ablation of the lumbar sympathetic chain using 5% phenol. Four patients were diabetic, two of whom had undergone previous sympathectomy on the same side. Within fifteen minutes of injection, all patients showed a rise in skin temperature in parts of the sock distribution of between 0.8 degrees C and 8.5 degrees C. We conclude that the haemodynamic effects of CLS are immediate and can be objectively measured with thermal imaging. PMID: 8195656, UI: 94253644

To: Prospector who wrote (535)	6/5/1998 1:45:00 AM
From: chirodoc	Read Replies (4) \| Respond to of 6039

THIS IS A POST EVERYONE SHOULD READ!!!!! MR. PACKER, PRESIDENT OF COII, IN RESPONSE TO MY EMAIL RESPONDS TO CONCERNS REGARDING PATENTS: ------------------------------------------------------------- Dear Curtis I appreciate your interest in CTI. As you have correctly observed, CTI's product is different from other equipment on the market. I can appreciate your interest in a comparison of our technology to others available or being developed. As you know, there are a number of other technologies that are directed at solving the issues of better detection of Breast cancer. Some are radiological based (digital mammograms, for example), others use ultrasound or lasers. Others use various forms of heat detection including heat sensitive chemical patches and infrared cameras. I am aware of these other technologies and the companies developing them. Their efforts do not diminish the contribution that I believe CTI will make in the field. We routinely track their progress. Each technology has inherent advantages and disadvantages and each company has strengths and weaknesses. They also track us. We are frequently the subject of what can be best described as "fishing" expeditions seeking the details of our developments. CTI has developed a number of key breakthroughs from our ten years of research and our clinical experience. These breakthroughs are at the heart of how we configure and apply our technology. A description of how we are different from anything else on the market would essentially be a roadmap for our competitors. That, obviously, would not be in the interest of the company or our shareholders. We have taken extensive measures to protect our developments. This includes patents, copyrights and other protections. We are presently preparing other patent applications. Again, a description of what we have chosen to patent, or otherwise protect, could also give a competitor insight into those items we feel are critical. Although much of this information will eventually become public knowledge, it is not in our interest to accelerate that process at this time. Again, I appreciate your interest in and support of CTI. As you know, we are limited in what we can say right now because we are in a securities registration period. I trust that you understand why, even when those restrictions are lifted, we will continue to limit discussion in a few key areas . Sincerely, David Packer, President Computerized Thermal Imaging